Skip to main content
Terug
BVNRY logo

Bavarian Nordic A/S

Datakwaliteit: 100%
BVNRY
OTC Healthcare Biotechnology
€ 9,64
▼ € 0,01 (-0,10%)
Marktkapitalisatie: 2,27B
Ook genoteerd als BVNKF OTC
Dagbereik
€ 9,64 € 9,64
52-Weeksbereik
€ 6,60 € 13,00
Volume
100
50D / 200D Gem.
€ 10,05 / € 10,63
Vorige Slotkoers
€ 9,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 1,7 0,3
P/B 0,2 2,9
ROE % 10,9 3,7
Net Margin % 22,3 3,8
Rev Growth 5Y % 33,0 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,00
€ 0,00 – € 0,00
 35 B 0
FY2026 € 4,93
€ 4,67 – € 5,33
 5,2 B 1

Belangrijkste Punten

Revenue grew 32,98% annually over 5 years — strong growth
Earnings grew 33,87% over the past year
ROE of 10,90% — decent returns on equity
Net margin of 22,29% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 2,42B in free cash flow

Groei

Revenue Growth (5Y)
32,98%
Revenue (1Y)3,81%
Earnings (1Y)33,87%
FCF Growth (3Y)313,11%

Kwaliteit

Return on Equity
10,90%
ROIC5,11%
Net Margin22,29%
Op. Margin14,92%

Veiligheid

Debt / Equity
0,01
Current Ratio4,22
Interest Coverage70,08

Waardering

P/E Ratio
1,71
P/B Ratio0,18
EV/EBITDA0,77
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,81% Revenue Growth (3Y) -8,34%
Earnings Growth (1Y) 33,87% Earnings Growth (3Y) -5,31%
Revenue Growth (5Y) 32,98% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,93B Net Income (TTM) 1,32B
ROE 10,90% ROA 8,84%
Gross Margin 47,39% Operating Margin 14,92%
Net Margin 22,29% Free Cash Flow (TTM) 2,42B
ROIC 5,11% FCF Growth (3Y) 313,11%
Safety
Debt / Equity 0,01 Current Ratio 4,22
Interest Coverage 70,08 Dividend Yield 0,00%
Valuation
P/E Ratio 1,71 P/B Ratio 0,18
P/S Ratio 0,38 PEG Ratio 0,32
EV/EBITDA 0,77 Dividend Yield 0,00%
Market Cap 2,27B Enterprise Value 681,83M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,93B 5,72B 7,06B 3,15B 1,90B
Net Income 1,32B 987,98M 1,48B -347,38M -464,78M
EPS (Diluted) 5,66 4,20 6,41 -1,64 -2,46
Gross Profit 2,81B 2,82B 4,53B 1,70B 570,32M
Operating Income 885,42M 939,77M 1,50B -3,85M -263,31M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,95B 14,41B 14,35B 12,39B 12,09B
Total Liabilities 2,08B 3,00B 4,01B 5,24B 4,71B
Shareholders' Equity 12,87B 11,41B 10,34B 7,15B 7,37B
Total Debt 130,86M 128,25M 145,30M 1,76B 1,13B
Cash & Equivalents 1,71B 1,62B 1,48B 575,41M 591,82M
Current Assets 6,74B 5,79B 5,40B 4,48B 4,75B
Current Liabilities 1,60B 2,80B 2,79B 2,29B 1,91B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#644 of 827
30
Value Defensive Investing (Benjamin Graham)
#407 of 709
25

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026